{
  "id": "substance-p",
  "title": "Substance P",
  "lang": "en",
  "source_lang": "en",
  "summary": "Substance P is an eleven-amino-acid signaling peptide involved in sensory transmission, neurogenic inflammation, and the vomiting reflex, acting mainly through neurokinin-1 receptors.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [
    "SP"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/substance-p/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/substance-p/",
      "json": "https://aiwiki.page/zh/substance-p.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Substance P is an eleven-amino-acid neuropeptide belonging to the tachykinin family. It acts as a neurotransmitter and neuromodulator in the central and peripheral nervous systems and also participates in communication between nerves and other tissues. Its principal receptor is the neurokinin-1 receptor (NK1 receptor). Substance P is best known for its involvement in the transmission and modulation of potentially damaging sensory stimuli, neurogenic inflammation, and the vomiting reflex, but it is not a signal specific to any single physiological process."
    },
    {
      "heading": "Molecular structure and synthesis",
      "text": "The amino-acid sequence of mature substance P is:\n\nArg–Pro–Lys–Pro–Gln–Gln–Phe–Phe–Gly–Leu–Met–NH₂\n\nThe terminal –NH₂ denotes amidation of the carboxyl terminus. This modification is important for biological activity. Substance P shares a conserved carboxyl-terminal sequence with other tachykinins, helping explain their overlapping receptor interactions.\n\nIn humans, substance P is produced from precursor proteins encoded by the TAC1 gene, historically called the preprotachykinin A gene. Through alternative splicing and subsequent processing, TAC1 also gives rise to other tachykinin peptides, including neurokinin A. Substance P is therefore not synthesized directly as a free eleven-residue peptide: a larger precursor is translated and then cleaved and chemically modified.\n\nIn neurons, the mature peptide is packaged in large dense-core vesicles. Release occurs through calcium-dependent exocytosis, often during sustained or relatively intense neuronal activity. Unlike small-molecule transmitters that can be synthesized locally at nerve terminals, neuropeptide precursors are generally produced in the cell body and transported toward release sites."
    },
    {
      "heading": "Receptors and signaling",
      "text": "Substance P preferentially activates the NK1 receptor, encoded in humans by TACR1. NK1 is a G protein-coupled receptor rather than a directly gated ion channel. Its activation can stimulate phospholipase C signaling, mobilize intracellular calcium, and activate protein kinase pathways. The resulting effects depend on the cell type, receptor abundance, and signaling context.\n\nThe receptor preferences of tachykinins are relative rather than absolute. At sufficiently high concentrations, substance P can activate other tachykinin receptors; conversely, other tachykinins can activate NK1 receptors. Experimental responses to large peptide doses therefore do not necessarily identify the receptor or mechanism responsible under physiological conditions.\n\nAfter activation, NK1 receptors can undergo desensitization and internalization. Substance P is also broken down by extracellular peptide-degrading enzymes, including neprilysin. Enzymatic degradation and receptor trafficking help determine the duration and spatial extent of its actions."
    },
    {
      "heading": "Sensory transmission and pain",
      "text": "Substance P occurs in subsets of primary sensory neurons, including small-diameter neurons whose peripheral endings respond to potentially damaging mechanical, thermal, or chemical stimuli. Their central terminals release substance P in the dorsal horn of the spinal cord, often alongside glutamate.\n\nWhereas glutamate commonly mediates rapid excitatory signaling, substance P can produce slower, longer-lasting changes in neuronal excitability. It contributes to nociception—the neural processing of potentially tissue-damaging stimuli—and can participate in the increased responsiveness of sensory pathways following injury or inflammation.\n\nNociception is not identical to the conscious experience of pain. Pain depends on activity across distributed nervous-system networks, together with cognitive and emotional factors. Substance P is one contributor to these processes, not a complete molecular explanation of pain."
    },
    {
      "heading": "Neurogenic inflammation and tissue effects",
      "text": "Substance P can also be released from peripheral sensory nerve endings. Its local actions contribute to neurogenic inflammation, in which nerve-derived mediators influence blood vessels, immune cells, and surrounding tissues.\n\nDepending on the tissue and experimental conditions, substance P can increase vascular permeability, promote plasma leakage, and alter immune-cell activity. These effects connect sensory signaling with inflammation. Substance P can also influence smooth-muscle contraction and secretion, particularly in the gastrointestinal and respiratory systems.\n\nIts interactions with the immune system are context-dependent. Effects have been described on macrophages, mast cells, and other immune populations, including changes in cytokine production. Not all such effects are mediated exclusively by NK1 receptors: substance P can activate the mast-cell receptor MRGPRX2 in some settings. Results vary with species, tissue, peptide concentration, and experimental method."
    },
    {
      "heading": "Vomiting and clinical pharmacology",
      "text": "Substance P–NK1 signaling has an established role in neural circuits that coordinate vomiting, including pathways in the brainstem. This role led to the development of NK1 receptor antagonists such as aprepitant and its prodrug fosaprepitant.\n\nThese medicines are used in defined clinical settings to prevent nausea and vomiting, notably in combination regimens associated with certain cancer treatments. Some NK1 antagonists also have uses in preventing postoperative nausea and vomiting. Their effectiveness demonstrates the importance of this signaling pathway in emesis, but does not imply that NK1 blockade is effective for every condition involving substance P.\n\nDespite extensive experimental evidence linking substance P to nociceptive signaling, NK1 antagonists have not become established general-purpose analgesics. This difference between experimental mechanisms and clinical outcomes illustrates the complexity and redundancy of pain pathways."
    },
    {
      "heading": "Discovery and research methods",
      "text": "Ulf von Euler and John Gaddum described substance P in 1931 while studying tissue extracts that produced effects including intestinal contraction and reduced blood pressure. The name originally referred to an active preparation before its molecular identity was established. Its amino-acid sequence was determined in 1971, enabling chemical synthesis and more specific investigation.\n\nModern studies use methods including immunohistochemistry to map peptide-containing cells and fibers, mass spectrometry to identify peptides, and receptor-selective compounds or genetic manipulations to investigate function.\n\nInterpretation requires care. Detecting substance P in a tissue does not establish when it is released or which cells respond to it. Measured concentrations can be affected by sample handling and peptide degradation, while antibody-based assays require adequate specificity. Changes in substance P levels alone do not establish a causal role in a disease or constitute a generally applicable diagnostic biomarker."
    }
  ],
  "links": [
    "amino-acid",
    "neuropeptide",
    "neurotransmitter",
    "gene",
    "alternative-splicing",
    "neuron",
    "ion-channel",
    "enzyme",
    "nociception",
    "inflammation",
    "immune-system",
    "macrophage",
    "cytokine",
    "cancer",
    "immunohistochemistry",
    "mass-spectrometry",
    "biomarker"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}